Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Protagonist Therapeutics
ISIN US74366E1029
|WKN A2AP32
Market cap (in EUR)
5,650 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 5,650 m |
| EPS, EUR | -1.56 |
| P/B ratio | 10.1 |
| P/E ratio | 137.5 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 41 m |
| Net income, EUR | -115 m |
| Profit margin | -282.83% |
What ETF is Protagonist Therapeutics in?
There are 34 ETFs which contain Protagonist Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Protagonist Therapeutics is the Franklin ClearBridge US Smaller Companies UCITS ETF Acc.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.